Eli Lilly Gains FDA Nod for Eight-Week Ebglyss Dosing, Six Injections Annually
LLY•Eli Lilly’s Ebglyss has received FDA approval for an eight-week maintenance dosing option, reducing injections to six per year for moderate-to-severe atopic dermatitis patients aged 12 and older. Phase 3 ADjoin extension data over 32 weeks showed consistent safety with no new signals or treatment discontinuations, potentially strengthening long-term revenue outlook.
1. FDA Approves Eight-Week Ebglyss Maintenance
The FDA approval extends maintenance dosing for Ebglyss to every eight weeks for patients aged 12 and older with moderate-to-severe atopic dermatitis, reducing the annual treatment burden to six injections versus the previous once-monthly regimen.
2. ADjoin Study Supports Safety and Durability
Phase 3 ADjoin extension data over a 32-week period evaluated both four-week and eight-week maintenance dosing, finding no new safety signals or patient discontinuations and reinforcing the drug’s long-term tolerability and efficacy.
3. Stock Reaction and Market Implications
Shares of Eli Lilly fell 0.39% in regular trading and slid a further 0.23% in after-hours following the announcement, while retail watcher counts rose 1.7% and message volume jumped 580%, indicating heightened investor focus on expanded immunology growth drivers.
